Patents by Inventor Karl-Heinz Herzig

Karl-Heinz Herzig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11804290
    Abstract: Highblood levels of very low density lipoprotein lipids (VLDLs) and glycoprotein acyl (Glyc A) are known to increase risk of diabetes, cardiovascular diseases, inflammations, cognitive impairments, cancers and premature deaths in sedentary persons. The invention determines physical activity thresholds of daily steps and accelerations to reduce plasma concentrations of VLDLs and Glyc A. The method and device is an accelerometer recording and classifying numbers of steps and accelerations and comparing the person's steps and accelerations with those shown to reduce VLDLs and Gly A. The invention is characterized in that if the daily number of accleration maxima exceeds the given en threshold of 2980 steps in the acceleration range 1.3-1.7 g, the person has performed physical activity, typically known to reduce circulating VLDLs and Glyc A.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: October 31, 2023
    Assignee: Gleap Health Technologies Oy
    Inventors: Juhani Leppäluoto, Sirkka Keinänen-Kiukaanniemi, Timo Jämsä, Jari Jokelainen, Karl-Heinz Herzig
  • Publication number: 20200202995
    Abstract: Highblood levels of very low density lipoprotein lipids (VLDLs) and glycoprotein acyl (Glyc A) are known to increase risk of diabetes, cardiovascular diseases, inflammations, cognitive impairments, cancers and premature deaths in sedentary persons. The invention determines physical activity thresholds of daily steps and accelerations to reduce plasma concentrations of VLDLs and Glyc A. The method and device is an accelerometer recording and classifying numbers of steps and accelerations and comparing the person's steps and accelerations with those shown to reduce VLDLs and Gly A. The invention is characterized in that if the daily number of accleration maxima exceeds the given en threshold of 2980 steps in the acceleration range 1.3-1.7 g, the person has performed physical activity, typically known to reduce circulating VLDLs and Glyc A.
    Type: Application
    Filed: August 29, 2018
    Publication date: June 25, 2020
    Applicant: Gleap Health Technologies Oy
    Inventors: Juhani LEPPÄLUOTO, Sirkka KEINÄNEN-KIUKAANNIEMI, Timo JÄMSÄ, Jari JOKELAINEN, Karl-Heinz HERZIG
  • Publication number: 20190290191
    Abstract: Discloses are method and device determining threshold values for the volume and intensity of physical activity and the lowest levels of this activity that reduce risk factors in overweight persons who suffer from disorders of sugar and lipid metabolism. The method comprises of registering a person's daily physical activity, comparing it with the measured/predetermined threshold levels and informs the person, if the volume and/or intensity of the physical activity has been sufficient to prevent the effects of disease risk factors. Based on the disclosed methodology, overweight persons having disorders in sugar and lipid metabolism are able to perform physical activity maintaining health and reducing the risk factors. The invention described herein demonstrates a novel opportunity for overweight people having an abnormal blood sugar to use the low intensity physical activity to restrain risk factors related to cardiovascular diseases, diabetes and obesity.
    Type: Application
    Filed: June 12, 2019
    Publication date: September 26, 2019
    Applicant: Gleap Health Technologies Oy
    Inventors: Juhani LEPPÄLUOTO, Karl-Heinz HERZIG, Riikka AHOLA, Timo JÄMSÄ, Jari JOKELAINEN, Sirkka KEINÄNEN-KIUKAANNIEMI
  • Patent number: 7202280
    Abstract: Novel methods for treating and preventing acute and/or chronic pancreatitis are described. Additionally, novel methods for inducing liver regeneration are described. The methods may comprise administering to a patient an effective amount of a metabolically stable analogue of spermidine and/or spermine. Preferred compounds for use in the methods may include 1-methylspermidine, 1-methylspermine and 1,12-dimethylspermine.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: April 10, 2007
    Inventors: Tiina-Liisa Räsänen, Leena Alhonen, Riitta Sinervirta, Tuomo Keinänen, Karl-Heinz Herzig, Alex Radii Khomutov, Jouko Vepsäläinen, Juhani Jänne
  • Publication number: 20040180968
    Abstract: Novel methods for treating and preventing acute and/or chronic pancreatitis are described. Additionally, novel methods for inducing liver regeneration are described. The methods may comprise administering to a patient an effective amount of a metabolically stable analogue of spermidine and/or spermine. Preferred compounds for use in the methods may include 1-methylspermidine, 1-methylspermine and 1,12-dimethylspermine.
    Type: Application
    Filed: December 9, 2003
    Publication date: September 16, 2004
    Inventors: Tiina-Liisa Rasanen, Leena Alhonen, Riitta Sinervirta, Tuomo Keinanen, Karl-Heinz Herzig, Alex Radii Khomutov, Jouko Vepsalainen, Juhani Janne
  • Patent number: 4013826
    Abstract: A high-voltage overhead transmission line with masts, insulator chains and conductor cables attached to high-strength guy lines and with ground wires is disclosed comprising a plurality of guyed masts with thrust footings forming support positions each with at least two support points in a plane normal to the conductor cables. Each guy line passes over at least two support points and is anchored to the ground at its ends. The guyed masts of each support position and the guy wires in the rigging field are tied together in an approximately horizontal plane by catenary-arranged insulators. The conductor cables are suspended from the network thus formed.
    Type: Grant
    Filed: July 9, 1975
    Date of Patent: March 22, 1977
    Assignee: BBC Brown, Boveri & Cie
    Inventor: Karl-Heinz Herzig